IPCALAB — Ipca Laboratories Share Price
0.000.00%
Last trade - 00:00- IN₹367.77bn
- IN₹384.33bn
- IN₹89.40bn
- 97
- 11
- 65
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 30.8 | ||
| PEG Ratio (f) | 1.49 | ||
| EPS Growth (f) | 26.01% | ||
| Dividend Yield (f) | 0.37% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.29 | ||
| Price to Tang. Book | 5.45 | ||
| Price to Free Cashflow | 67.39 | ||
| Price to Sales | 4.11 | ||
| EV to EBITDA | 25.27 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.98% | ||
| Return on Equity | 11.11% | ||
| Operating Margin | 12.57% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 54,199.9 | 58,297.9 | 62,443.2 | 77,050.4 | 89,395.9 | 99,158.4 | 111,168.86 | 13.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +85.31 | -22.97 | -48.21 | +41.78 | +34.25 | +27.02 | +23.98 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Directors
- Premchand Godha CHM (73)
- Ajit Jain CFO (65)
- E. Babu CEX (57)
- Pabitra Bhattacharya CEX (51)
- Sunil Ghai CEX (58)
- Sanjay Kapadia CEX (59)
- Ashok Kumar CEX (67)
- Shashil Mendonsa CEX (48)
- Goutam Muhuri CEX (62)
- Anil Pareek CEX (62)
- Kavita Sehwani CEX (50)
- Sanjay Sinha CEX (62)
- Avadhut Sukhtankar CEX (68)
- Harish Kamath CCO (61)
- Pranay Godha EDR (48)
- Prashant Godha EDR (46)
- Anand Kusre NID
- Manisha Premnath NID
- Kamal Seth NID (75)
- Dev Yadava NID
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- October 19th, 1949
- Public Since
- February 23rd, 1994
- No. of Shareholders
- 89,020
- No. of Employees
- 18,043
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 253,704,218
- Address
- 125,, MUMBAI, 400067
- Web
- https://www.ipca.com/
- Phone
- +91 2262105000
- Contact
- Harish Kamath
- Auditors
- Natvarlal Vepari & Co.
Upcoming Events for IPCALAB
Q1 2026 IPCA Laboratories Ltd Earnings Release
Ipca Laboratories Ltd Annual Shareholders Meeting
Q2 2026 IPCA Laboratories Ltd Earnings Release
Similar to IPCALAB
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Ipca Laboratories share price?
As of Today at 21:22 UTC, shares in Ipca Laboratories are trading at IN₹1,449.60. This share price information is delayed by 15 minutes.
How has the Ipca Laboratories share price performed this year?
Shares in Ipca Laboratories last closed at IN₹1,449.60 and the price had moved by +18.45% over the past 365 days. In terms of relative price strength the Ipca Laboratories share price has outperformed the S&P BSE 100 Index by +16.07% over the past year.
What are the analyst and broker recommendations for Ipca Laboratories?
The overall consensus recommendation for Ipca Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ipca Laboratories dividend yield?
The Ipca Laboratories dividend yield is 0.28% based on the trailing twelve month period.
Does Ipca Laboratories pay a dividend?
Last year, Ipca Laboratories paid a total dividend of IN₹4.00, and it currently has a trailing dividend yield of 0.28%.Looking ahead, shares in Ipca Laboratories are due to go ex-dividend on 2025-08-05 and the next dividend pay date is 2025-09-01.
When does Ipca Laboratories next pay dividends?
Ipca Laboratories are due to go ex-dividend on 2025-08-05 and the next dividend pay date is 2025-09-01. The historic dividend yield on Ipca Laboratories shares is currently 0.28%.
How do I buy Ipca Laboratories shares?
To buy shares in Ipca Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ipca Laboratories?
As of the previous close price of IN₹1,449.60, shares in Ipca Laboratories had a market capitalisation of IN₹367.77bn.
Where are Ipca Laboratories shares listed?
Here are the trading details for Ipca Laboratories:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: IPCALAB
What kind of share is Ipca Laboratories?
Based on an overall assessment of its quality, value and momentum Ipca Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ipca Laboratories share price forecast for 2025?
The analyst consensus target price for shares in Ipca Laboratories is IN₹1,594.73. That is 10.01% above the last closing price of IN₹1,449.60.
Analysts covering Ipca Laboratories currently have a consensus Earnings Per Share (EPS) forecast of IN₹44.09 for the next financial year.
Find out moreWhat is the trend in the Ipca Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ipca Laboratories. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -18.69%.
As of the last closing price of IN₹1,449.60, shares in Ipca Laboratories were trading -2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ipca Laboratories PE Ratio?
The Ipca Laboratories PE ratio based on its reported earnings over the past 12 months is 30.8. The shares last closed at IN₹1,449.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ipca Laboratories?
Ipca Laboratories' management team is headed by:
- Premchand Godha - CHM
- Ajit Jain - CFO
- E. Babu - CEX
- Pabitra Bhattacharya - CEX
- Sunil Ghai - CEX
- Sanjay Kapadia - CEX
- Ashok Kumar - CEX
- Shashil Mendonsa - CEX
- Goutam Muhuri - CEX
- Anil Pareek - CEX
- Kavita Sehwani - CEX
- Sanjay Sinha - CEX
- Avadhut Sukhtankar - CEX
- Harish Kamath - CCO
- Pranay Godha - EDR
- Prashant Godha - EDR
- Anand Kusre - NID
- Manisha Premnath - NID
- Kamal Seth - NID
- Dev Yadava - NID